Drug Profile
APTA 16
Alternative Names: APTA-16; SJP-1604Latest Information Update: 08 Feb 2022
Price :
$50
*
At a glance
- Originator AptaBio Therapeutics
- Class Antineoplastics; Drug conjugates; Nucleotide aptamers; Small molecules
- Mechanism of Action Histone methyltransferase inhibitors; Nucleolin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- Discontinued Liver cancer
Most Recent Events
- 08 Feb 2022 Phase-I clinical trials in Acute myeloid leukaemia in South Korea (Parenteral) (AptaBio Therapeutics pipeline, February 2022)
- 08 Feb 2022 Phase-I clinical trials in Myelodysplastic syndromes in South Korea (Parenteral) (AptaBio Therapeutics pipeline, February 2022)
- 10 Apr 2021 Samjin Pharma plans a phase I pharmacokinetic trial for Acute myeloid leukaemia